Haemonetics Corporation, a healthcare company, provides hematology products and solutions.
Proven track record with reasonable growth potential.
Share Price & News
How has Haemonetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HAE's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: HAE exceeded the US Medical Equipment industry which returned -4.5% over the past year.
Return vs Market: HAE exceeded the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is Haemonetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHow Does Haemonetics's (NYSE:HAE) P/E Compare To Its Industry, After The Share Price Drop?
2 weeks ago | Simply Wall StWith EPS Growth And More, Haemonetics (NYSE:HAE) Is Interesting
1 month ago | Simply Wall StIs Haemonetics Corporation’s (NYSE:HAE) 16% ROCE Any Good?
Is Haemonetics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HAE ($99.65) is trading below our estimate of fair value ($136.22)
Significantly Below Fair Value: HAE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HAE is poor value based on its PE Ratio (63.6x) compared to the Medical Equipment industry average (39x).
PE vs Market: HAE is poor value based on its PE Ratio (63.6x) compared to the US market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: HAE is poor value based on its PEG Ratio (2.3x)
Price to Book Ratio
PB vs Industry: HAE is overvalued based on its PB Ratio (8.7x) compared to the US Medical Equipment industry average (3x).
How is Haemonetics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HAE's forecast earnings growth (28% per year) is above the savings rate (1.7%).
Earnings vs Market: HAE's earnings (28% per year) are forecast to grow faster than the US market (12.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HAE's revenue (6.2% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: HAE's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HAE's Return on Equity is forecast to be high in 3 years time (28.9%)
How has Haemonetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HAE has a large one-off loss of $54.5M impacting its December 28 2019 financial results.
Growing Profit Margin: HAE's current net profit margins (8%) are higher than last year (4.8%).
Past Earnings Growth Analysis
Earnings Trend: HAE's earnings have grown significantly by 41.6% per year over the past 5 years.
Accelerating Growth: HAE's earnings growth over the past year (74.1%) exceeds its 5-year average (41.6% per year).
Earnings vs Industry: HAE earnings growth over the past year (74.1%) exceeded the Medical Equipment industry 1%.
Return on Equity
High ROE: HAE's Return on Equity (13.9%) is considered low.
How is Haemonetics's financial position?
Financial Position Analysis
Short Term Liabilities: HAE's short term assets ($582.6M) exceed its short term liabilities ($256.7M).
Long Term Liabilities: HAE's short term assets ($582.6M) exceed its long term liabilities ($406.5M).
Debt to Equity History and Analysis
Debt Level: HAE's debt to equity ratio (66.2%) is considered high.
Reducing Debt: HAE's debt to equity ratio has increased from 51.4% to 66.2% over the past 5 years.
Debt Coverage: HAE's debt is well covered by operating cash flow (34.8%).
Interest Coverage: HAE's interest payments on its debt are well covered by EBIT (10.2x coverage).
Inventory Level: HAE has a high level of physical assets or inventory.
Debt Coverage by Assets: HAE's debt is covered by short term assets (assets are 1.5x debt).
What is Haemonetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HAE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate HAE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HAE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HAE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HAE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Simon (55yo)
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016. He joined Haemonetics in May 2016. Mr. Simon served as a Sen ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD8.55M) is about average for companies of similar size in the US market ($USD7.33M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
|CEO, President & Director||3.92yrs||US$8.55m||0.51% $25.5m|
|CFO & Executive VP||3.67yrs||US$2.31m||no data|
|Executive VP||no data||US$2.15m||0.0074% $369.9k|
|Senior Vice President of Global Human Resources||3.08yrs||US$1.49m||0.0087% $436.6k|
|Principal Accounting Officer||4yrs||no data||0.0049% $244.1k|
|Vice President of Investor Relations||8.67yrs||no data||no data|
|Senior Vice President of Corporate Development & Planning||2.83yrs||no data||no data|
|Senior Vice President of Global Quality & Regulatory Affairs||3.08yrs||no data||no data|
|Senior Vice President of Global Business Services||3yrs||no data||no data|
|President of International||2.92yrs||no data||no data|
Experienced Management: HAE's management team is considered experienced (3.1 years average tenure).
|CEO, President & Director||3.92yrs||US$8.55m||0.51% $25.5m|
|Independent Director||2.5yrs||US$245.06k||0.0058% $289.7k|
|Independent Chairman||8.83yrs||US$419.94k||0.057% $2.9m|
|Lead Director||no data||US$262.94k||0.093% $4.7m|
|Independent Director||2.25yrs||US$249.94k||0.0026% $129.8k|
|Independent Director||1yr||no data||no data|
|Independent Director||14.25yrs||US$245.06k||0.041% $2.0m|
|Independent Director||3.5yrs||US$254.80k||0.017% $857.2k|
|Independent Director||5.75yrs||US$266.94k||0.034% $1.7m|
Experienced Board: HAE's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HAE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Haemonetics Corporation's company bio, employee growth, exchange listings and data sources
- Name: Haemonetics Corporation
- Ticker: HAE
- Exchange: NYSE
- Founded: 1971
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$5.013b
- Shares outstanding: 50.30m
- Website: https://www.haemonetics.com
Number of Employees
- Haemonetics Corporation
- 125 Summer Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HAE||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 1991|
|HAZ||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1991|
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through Japan, EMEA, North America Plasma, and All Other segments. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables, such as plasma collection containers and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/01 06:57|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.